All data are based on the daily closing price as of October 8, 2026
m
Medy-Tox
086900.KQ
49.03 USD
-1.40
-2.78%
Overview
Last close
49.03 usd
Market cap
316.68M usd
52 week high
131.45 usd
52 week low
46.23 usd
Target price
68.46 usd
Valuation
P/E
N/A
Forward P/E
20.6612
Price/Sales
1.708
Price/Book Value
1.1625
Enterprise Value
380.92M usd
EV/Revenue
2.0938
EV/EBITDA
69.3982
Key financials
Revenue TTM
186.82M usd
Gross Profit TTM
115.33M usd
EBITDA TTM
27.64M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
369.54M usd
Net debt
48.91M usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.